Thymosin Apha 1–A Peptide Immune Modulator with a Broad Range of Clinical ApplicationsCynthia W. Tuthill* and Robert S. King
SciClone Pharmaceuticals Inc., 950 Tower Lane, Suite 900, Foster City, California, USA
- *Corresponding Author:
- Cynthia W. Tuthill, PhD
SciClone Pharmaceuticals Inc.
950 Tower Lane, Suite 900
Foster City, CA 94404, USA
E-mail: [email protected]
Received date: June 27, 2013; Accepted date: September 24, 2013; Published date: October 01, 2013
Citation: Tuthill CW, King RS (2013) Thymosin Apha 1–A Peptide Immune Modulator with a Broad Range of Clinical Applications. Clin Exp Pharmacol 3:133. doi: 10.4172/2161-1459.1000133
Copyright: © 2013 Tuthill CW, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Thymosin alpha 1 (thymalfasin, Ta1), the active ingredient in ZADAXIN®, is a peptidic biological response modifier which activates various cells of the immune system. Ta1 is therefore expected to have clinical benefits in disorders where immune responses are impaired or ineffective, such as acute and chronic infections, cancers, and vaccine non-responsiveness, all of which are hallmarks of an impaired or inadequate immune response. Importantly, Ta1 acts without overstimulation of cytokine production and is generally well tolerated; it has an excellent safety profile and does not appear to induce the side effects and toxicities commonly associated with agents in this class such as interferonalpha and interleukin-2.
Ta1 has been shown to act through Toll-like receptors, linking to intracellular cell-signaling pathways and leading to stimulation of the immune system, including T helper cells, cytotoxic T cells, and natural killer cells.
Clinical studies with Ta1 have been conducted and shown evidence of benefit in subjects with acute or chronic viral or bacterial infections, including subjects with severe sepsis, infections after bone marrow transplant, chronic hepatitis B or C, or acquired immune deficiency syndrome. Ta1 has also shown promise in clinical evaluation as an adjunctive treatment in subjects suffering from various types of cancer, including hepatocellular carcinoma, non-small-cell lung cancer, melanoma, renal, breast and gastric cancers; and in subjects receiving vaccines (geriatric subjects receiving influenza vaccine and subjects with renal failure receiving influenza or hepatitis vaccine).